个人简介

Williamhill中文教授、博士生导师、逸仙学者。2015年获william威廉英国医学博士学位，2019年获聘副教授职务，2025年获聘教授职务。广东省干体细胞临床研究质量控制中心办公室副主任，广东省健康管理学会干细胞与再生医学专业委员会常委，广东省精准医学应用学会精准血液病分会委员会常委，广东省病理生理学会第一届监事会监事。
主要研究方向为间充质干细胞（MSC）治疗机理与转化，揭示MSC功能特性并建立评价标准，发现MSC作用靶点且解析治疗机理，推进MSC治疗重大难治性疾病的临床转化。作为第一或通讯作者（含共一/共通讯）在Leukemia, J Hematol Oncol, Mol Ther, EBioMedicine, Cell Mol Immunol.等杂志发表学术论文近20篇，作为执笔人制定《人间充质干细胞》（T/CSCB 0003-2021）、《人间充质干细胞血液相容性评估技术规范》（T/CSCB 0003-2021）(T/CSCB 0026-2024)等标准；研究成果荣获中华医学科技奖-青年科技奖、广东省自然科学奖一等奖、广东医学科技奖一等奖、第27届国际器官移植大会（TTS） “Young Investigator Scientific Award”等。近年来承担了国家自然科学基金面上项目、广东省自然科学基金杰出青年基金项目、广州市珠江科技新星专项等，参与国家重点研发计划、省重点领域研发计划等项目。

近5年发表的学术论文

  1. Ma Y#, Chen J#, Fan Z#, Shi J, Li G, Li X, Wang T, Xu N, Liu J, Li Z, Li H, Zhang X, Lin D, Song W, Liu Q*, Huang W*, Chen X*, Xiang AP*. Dynamic forecasting module for chronic graft-versus-host disease progression based on a disease-associated subpopulation of B cells: a multicenter prospective study. EBioMedicine. 2025; 113:105587. 
  2. Bao Y#, Liu J#, Li Z#, Sun Y#, Chen J, Ma Y, Li G, Wang T, Liu H, Zhang X, Yan R, Yao Z, Guo X, Fang R, Feng J, Xia W*, Xiang AP*, Chen X*. Ex vivo-generated human CD1c+ regulatory B cells by a chemically defined system suppress immune responses and alleviate graft-versus-host disease. Mol Ther. 2024;32(12):4372-4382. 
  3. Liu J#, Lai X#, Bao Y#, Xie F, Li Z, Chen J, Li G, Wang T, Huang W, Ma Y, Shi J, Zhao E, Xiang AP*, Liu Q*, Chen X*. Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells. Front Immunol. 2022,13:853894. 
  4. Zhao K#, Lin R#, Fan Z#, Chen X#, Wang Y#, Huang F, Xu N, Zhang X, Zhang X, Xuan L, Wang S, Lin D, Deng L, Nie D, Weng J, Li Y, Zhang X, Li Y, Xiang AP*, Liu Q*. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22. 
  5. Chen X#, Huang J#, Wu J#, Hao J#, Fu B, Wang Y, Zhou B, Na T, Wei J, Zhang Y, Li Q, Hu S, Zhou J, Yu J, Wu Z, Zhu H, Cao J, Wang L, Peng Y, Liang L, Ma A*, Zhang Y*, Zhao T*, Xiang AP*. Human mesenchymal stem cells. Cell Prolif. 2022; 55(4): e13141. 
  6. Wei Y#, Chen X#, Zhang H#, Su Q, Peng Y, Fu Q, Li J, Cao Y, Li X, Yang S, Ye Q, Huang H, Deng R, Li G, Xu B, Wu C, Wang J, Zhang X, Su X, Liu L*, Xiang P*, Wang C*. Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection after Kidney Transplantation- A Single-arm, Two-dosing-regimen, Phase I/II Study. Front Immunol. 2021,12:662441.
  7. Liu Q#, Chen X#, Liu C#, Pan L, Kang X, Li Y, Du C, Dong S, Xiang AP*, Zhang Q*, Xu Y*. Mesenchymal Stem Cells Alleviate Experimental Immune-mediated Liver Injury via Chitinase 3-like protein 1-mediated T cell suppression. Cell Death Dis.2021;12(3):240.
  8. Zheng S#, Huang K#, Xia W#, Shi J, Liu Q, Zhang X, Li G, Chen J, Wang T, Chen X*, Xiang AP. Mesenchymal stromal cells rapidly suppress TCR signaling-mediated cytokine transcription in activated T cells through the ICAM-1/CD43 interaction. Front Immunol. 2021,12:609544.